Takeda to appeal EU negative opinion on melatonin agonist ramelteon « GPCR News

Tags
5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
June 2008

M T W T F S S

« May Jul »

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30

Takeda to appeal EU negative opinion on melatonin agonist ramelteon

Posted on June 17, 2008 by crimsoncanary

Takeda has requested a re-examination of its European application for melatonin agonist ramelteoon. In May the CHMP recommended that the EU not approve ramelteon due to questions on its efficacy in the treatment of insomnia.

Filed under: gpcr | Tagged: Melatonin, MT1, MT2, ramelteon, regulatory, Rozerem, TAK-375, TAK375, Takeda

« Acadias ACP-104 does not meet endpoint in Phase IIb Schizophrenia trial Daiichi-Sankyos Angiotensin II 1 antagonist olmesartan reverses blood vessel damage »

Leave a Reply